CSTL (Castle Biosciences) Float Percentage Of Total Shares Outstanding: 97.64% (As of Jun. 28, 2026)


CSTL Castle Biosciences Inc CSTL
73 GF Score
Price $24.21
GF Value $29.16
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Castle Biosciences Float Percentage Of Total Shares Outstanding?

Castle Biosciences CSTL +6.07% 73 Float Percentage Of Total Shares Outstanding is 97.64% as of Jun. 28, 2026. GuruFocus rates CSTL with a GF Score™ of 73/100 and a GF Value™ of $29.16 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Castle Biosciences's float shares is 29.61 Mil. Castle Biosciences's total shares outstanding is 30.33 Mil. Castle Biosciences's float percentage of total shares outstanding is 97.64%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Castle Biosciences's Insider Ownership is 2.35%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Castle Biosciences's Institutional Ownership is 98.40%.

CSTL
73GF Score
Castle Biosciences Inc CSTL
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Castle Biosciences Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Castle Biosciences's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=29.61/30.33
=97.64%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 97.64% mean?
Castle Biosciences (CSTL) has a Float Percentage Of Total Shares Outstanding of 97.64% as of Jun. 28, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Castle Biosciences and its competitors.
Is Castle Biosciences' Float Percentage Of Total Shares Outstanding too high?
Castle Biosciences' current Float Percentage Of Total Shares Outstanding is 97.64%. Overall, Castle Biosciences has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Castle Biosciences' Float Percentage Of Total Shares Outstanding compare to FLGT and MYGN?
Castle Biosciences' Float Percentage Of Total Shares Outstanding of 97.64% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Medical Diagnostics & Research company?
A good Float Percentage Of Total Shares Outstanding depends on the Medical Diagnostics & Research industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Castle Biosciences and its competitors. Castle Biosciences's current Float Percentage Of Total Shares Outstanding is 97.64%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Castle Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Castle Biosciences (CSTL) is currently considered Modestly Undervalued. The stock's GF Value™ is $29.16, compared to a current price of $24.21 — trading 17% below its estimated fair value. The current Float Percentage Of Total Shares Outstanding is 97.64%. Castle Biosciences' overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For Castle Biosciences (CSTL), the current Float Percentage Of Total Shares Outstanding is 97.64% as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Castle Biosciences (CSTL) Overvalued in 2026?

Based on GuruFocus' analysis, Castle Biosciences stock appears to be undervalued. The current stock price of $24.21 is trading 17% below its estimated GF Value™ of $29.16. GuruFocus considers Castle Biosciences to be Modestly Undervalued.

Key valuation signals for CSTL:

  • Float Percentage Of Total Shares Outstanding: 97.64%
  • GF Value™: $29.16 vs. price of $24.21 (17% below fair value)
  • GF Score™: 73/100 with 4 warning signs

No single metric tells the full story. See the CSTL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Castle Biosciences Business Description

Other Exchanges 086:Germany
Address 1500 West Parkwood Avenue, Suite 401, Friendswood, TX, USA, 77546
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.
73GF Score

Get the complete analysis for CSTL

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$24.21
Price
$29.16
GF Value